# Avalanche Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avalanche-biotechnologies

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: www.avalanchebiotech.com
- Total disclosed funding: $55M
- Latest round: Series B (Apr 22, 2014)
- Investors on record: 6

## About

Avalanche Biotechnologies is a biotechnology company focused on developing innovative gene therapies aimed at treating eye diseases and other serious health conditions.Founded in 2006 and headquartered in Menlo Park, US, Avalanche Biotechnologies specializes in gene therapy solutions. Over the years, the company has pivoted towards ophthalmic applications, emphasizing its commitment to advancing medical treatment. In July 2014, the company raised USD 102 mn through an IPO, offering 6 million shares at USD 17 each, totaling its capital raised to USD 102 mn. The company has engaged in 3 deals to date.Avalanche Biotechnologies develops gene therapy products designed to address ocular diseases. Their primary offerings focus on harnessing gene transfer technology to introduce therapeutic genes into target cells, potentially revolutionizing treatment for conditions such as inherited retinal diseases. Their innovative platform aims to provide long-term solutions for patients suffering from debilitating visual impairments and other serious health issues, ensuring they can receive personalized and effective treatment options.In 2021, Avalanche Biotechnologies reported revenues of USD 7.5 mn. The company faced significant challenges with an EBITDA of USD -139.16 mn, reflecting the ongoing investment in research and development, as well as the costs associated with bringing new therapies to market.Looking ahead, Avalanche Biotechnologies aims to expand its portfolio of gene therapies with new products targeting additional eye diseases by 2025. The company plans to leverage the proceeds from its recent IPO to enhance R&D efforts and accelerate clinical trials for its leading candidates. Furthermore, the company is eyeing expansion into international markets, particularly in Europe and Asia, to broaden its patient reach and market presence. The initiatives will be supported by the capital raised, with an emphasis on advancing innovative treatments in the global healthcare landscape.

## Funding rounds

- Series B, Apr 22, 2014, $55M — Venrock, Adage Capital Management, Redmile Group, Deerfield Management, Rock Springs Capital, Sabby Capital

## Investors

- Venrock (https://capitalatlas.ai/funds/venrock) — Series B
- Adage Capital Management — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B
- Rock Springs Capital — Series B
- Sabby Capital (https://capitalatlas.ai/funds/sabby-capital) — Series B